November 4, 2025Q3 2025 Group Highlights Comparable order intake growth 8%Group sales amounted to EUR 4.3 billion, reflecting 3% increase in ...

Ball Corporation (NYSE: BALL) today reported third quarter 2025 results. References to net sales and comparable operating earnings in today's release do not include the company's former aerospace ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine calcium handling, and continued safety and efficacy ...

Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months– – Combination ...

The greatest college basketball coach of all time had a winning formula on the court. It works on the shop floor and in the C ...

India's top drug regulator cited insufficient evidence of efficacy in the two studies conducted by Serum Institute and ICMR.

Francis Guibernau is a Senior Adversary Research Engineer and member of the Adversary Research Team (ART) at AttackIQ. Francis conducts in-depth threat research and analysis to design and create ...

Travelmole caught up with Darryl Erasmus, Chief Operating Officer and Acting Chief Executive Officer for South African ...

This focus on standardization is helping reduce integration complexity—an ongoing challenge for many healthcare organizations ...

Fourth Quarter 2025 Diluted earnings per share (“EPS”) of $0.79 and Adjusted EPS of $1.70Fiscal Year 2025 Diluted EPS of ...

Q3 2025 Earnings Call Transcript October 31, 2025 LyondellBasell Industries N.V. beats earnings expectations. Reported EPS is ...